

FLAVOMYCIN® 10, 80 (flavophospholipol)

COMPOSITION

Content	Flavomycin® 10	Flavomycin® 80
Flavophospholipol	1 g	8 g
Excipients	up to 100 g	up to 100 g

Produced by fermentation of *Streptomyces ghanensis* (DSM 12218).

PHARMACOLOGICAL ACTION

The spectrum of activity covers economically important microorganisms which compete with the host animal for nutrients. Flavomycin® inhibits their reproduction by intervening in the biosynthesis of murein, the structural substance of their cell walls. Specifically, the enzyme glycosyltransferase, that plays an essential role in the synthesis of the cell wall of Gram-positive bacteria, cannot distinguish between flavophospholipol and the natural murein compound. This prevents murein synthesis from taking place. Damage to the murein layer causes cells to burst. However, the desirable *Lactobacilli* and *Bifidobacteria* are unharmed. Flavomycin® is one of the most active substances inhibiting murein biosynthesis and is therefore effective in very low doses. An antimicrobial with this mode of action is particularly suitable as a feed additive, as animal cells have no comparable vulnerable structure. This results in the extra-ordinarily high efficacy of and tolerability to Flavomycin®.

INDICATIONS

Flavomycin® is a performance enhancer for use in pigs, poultry, cattle, rabbits, and aquatic species. Flavomycin® allows for the early establishment of normal gut microflora by sparing beneficial lactic acid producing bacteria. Through its sparing effect on the beneficial intestinal microflora, Flavomycin® has been proven to be effective in reducing the shedding and infection rates of several harmful intestinal bacteria, such as *Salmonella spp.*, *Clostridium* and *E. coli*. Due to its effect on pathogenic bacteria, Flavomycin® contributes to a thinning of the intestinal wall, which leads to a better absorption of nutrients and specifically pigments, an improvement of litter quality, provides support of animals during stress situations, e.g., heat stress, etc. As no other member of the same antibiotic class, the phosphoglycolipids, has ever been developed for therapeutical use in humans or animals, Flavomycin® poses no risk of increasing the selection for antibiotic resistance in humans. Continuous research, dating back to the 1970's, reveals that Flavomycin® actually has the potential to reduce antibiotic resistance.

CONTRAINDICATIONS

Not established.

MODE OF ADMINISTRATION

Orally, following good homogenization with feed. In order to reach uniform homogenization with feed, it is recommended to mix the measured quantity of Flavomycin® (calculated on the basis of the prescribed dose) on stages in the following order: up to 10 kg feed; up to 100 kg feed; and up to 1000 kg feed.

TARGET SPECIES

Chickens, turkeys, pigs, rabbits, fish and shrimp, cattle.

DOSAGE

Species	Flavophospholipol ppm	Flavomycin® 10 g/ ton feed	Flavomycin® 80 g/ ton feed
Chickens for fattening	1 - 20	100 - 2000	12.5 - 250
Layers	2 - 5	200 - 500	25 - 62.5
Turkeys up to 26 weeks of age	1 - 20	100 - 2000	12.5 - 250
Piglets up to 3 months of age	10 - 25	1000 - 2500	125 - 312.5
Fattening pigs up to 6 months of age	1 - 20	100 - 2000	12.5 - 250
Rabbits up to 6 months of age	2 - 4	200 - 400	25 - 50
Calves up to 6 months of age	6 - 16	600 - 1600	75 - 200
Beef cattle	2 - 10	200 - 1000	25 - 125
Salmonids	4 - 40	400 - 4000	50 - 500
Carp species	2 - 8	200 - 800	25 - 100
Trout	4 - 8	400 - 800	50 - 100
Eel species	10 - 20	1000 - 2000	125 - 250
Tilapia	10 - 20	1000 - 2000	125 - 250
Shrimp	3 - 20	300 - 2000	37.5 - 250

SIDE EFFECTS

Not established.

WITHDRAWAL PERIOD

Zero (0) days.

As Flavomycin® is not absorbed from the digestive tract, no residues are found in blood or tissues.

STORAGE

In the original packing, well closed, in dry and well-ventilated facilities, protected from direct sunlight.

PACKING

20kg PE-lined multi-layer paper bags.

FURTHER INFORMATION

The product is stable under all practical pelleting and expanding conditions.